Literature DB >> 23040361

Osteo-articular manifestations of amyloidosis.

Pauline M'bappé1, Gilles Grateau.   

Abstract

Whether it is overload disease or mispleated proteins, amyloid is a great pretender. This is especially true for all of the osteo-articular manifestations of amyloid light chain (AL) amyloidosis, which may mimic rheumatoid arthritis, polymyalgia rheumatica, a myeloma or a bone tumour. To improve the prognosis, AL amyloidosis must be considered in front of atypical osteo-articular manifestations. Amyloidosis Ab2M of chronic haemodialysis (members' arthropathy and destructive spondylitis) is a specific entity that needs to be differentiated from other osteoarthropathies of chronic renal failure. It has become exceptional since the progress of haemodialysis. Finally transthyretin amyloidosis(ATTR) can be responsible for carpal tunnel syndrome(CTS) in its genetic and senile form. Although amyloidosis is rare, it represents one of the aetiologies of CSC, regardless of its type. In the specific context of haemodialysis, this poses no difficulty for the clinician. Yet AL amyloidosis must be considered more often, as must senile amyloidosis ATTR in the elderly. It seems obvious that the anatomo-pathologic analysis with specific staining with Congo red - see typing - should be systematically performed in the case of surgical neurolysis. Amyloidosis is defined by the extracellular deposit of proteins which share common tinctorial affinities, a fibril aspect under electron microscopy and spatial conformation called beta pleated. Once regarded as a mere overload disease, it is currently considered as a disease of misfolded proteins. Indeed, it is certain that abnormalities of spatial pattern play an essential role in the responsibility for the pathology of many proteins whose amyloid fibre is the final common way. They involve both changes in the conformation of proteins and other major in vivo interactions between amyloid protein and the extracellular matrix. In most cases, amyloidosis represents the bulk of histopathological lesions and its pathogenic role is certain. In other cases, it is only one elementary lesion of the disease and its role is controversial. The amyloidosis responsible for osteo-articular manifestations are the AL immunoglobulin amyloidosis, the beta2-microglobulin amyloidosis in patients under haemodialysis and finally the amyloidosis of transthyretin (genetic and senile). Rheumatological manifestations of immunoglobulin amyloidosis are numerous and often indicative of the disease. Deposits affect joint and periarticular structures. The most common presentation is a progressively developing bilateral symmetric polyarthritis with negative immunology and absent specific structural abnormalities. Carpal tunnel syndrome (CTS) is very common and should suggest the aetiology. Other clinical representations are rarer as an isolated bone tumour (amyloidoma) or integrating systemic AL amyloidosis. β 2-Microglobulin amyloidosis occurs in patients under chronic haemodialysis. It is responsible for CTS, arthralgia and above all a specific destructive spondyloarthropathy. The transthyretin amyloidosis also causes CTS.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23040361     DOI: 10.1016/j.berh.2012.07.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  14 in total

Review 1.  T2 black lesions on routine knee MRI: differential considerations.

Authors:  Vibhor Wadhwa; Gina Cho; Daniel Moore; Parham Pezeshk; Katherine Coyner; Avneesh Chhabra
Journal:  Eur Radiol       Date:  2015-09-29       Impact factor: 5.315

2.  [A 48-year-old patient with oligoarthritis of the knees, having excluded spondyloarthritis and rheumathoid arthritis].

Authors:  M Gehlen; S Janik; P Dudko; M Schwarz-Eywill
Journal:  Internist (Berl)       Date:  2014-04       Impact factor: 0.743

3.  Clinical and laboratory characteristics of patients having amyloidogenic transthyretin deposition in osteoarthritic knee joints.

Authors:  Ya-jun Gu; Peng Ge; Yun Mu; Jin-hai Lu; Fang Zheng; Xu-guo Sun
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

4.  The Amphipathic GM1 Molecule Stabilizes Amyloid Aggregates, Preventing their Cytotoxicity.

Authors:  Monica Bucciantini; Manuela Leri; Massimo Stefani; Ronald Melki; Sandra Zecchi-Orlandini; Daniele Nosi
Journal:  Biophys J       Date:  2020-06-12       Impact factor: 4.033

5.  Autoimmune response to transthyretin in juvenile idiopathic arthritis.

Authors:  Cristina C Clement; Halima Moncrieffe; Aditi Lele; Ginger Janow; Aniuska Becerra; Francesco Bauli; Fawzy A Saad; Giorgio Perino; Cristina Montagna; Neil Cobelli; John Hardin; Lawrence J Stern; Norman Ilowite; Steven A Porcelli; Laura Santambrogio
Journal:  JCI Insight       Date:  2016-02-25

Review 6.  Neuroarthropathy of the foot revealing primary systemic amyloidosis: case report and literature review.

Authors:  Irina Adriana Andrei; Thierry Kuntzer; Johannes Alexander Lobrinus; Arnaud Jaccard; Pascal Zufferey
Journal:  Clin Rheumatol       Date:  2014-09-18       Impact factor: 2.980

7.  Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging.

Authors:  E Kastritis; M Gavriatopoulou; M A Dimopoulos; E Eleutherakis-Papaiakovou; N Kanellias; M Roussou; C Pamboucas; S T Toumanidis; E Terpos
Journal:  Blood Cancer J       Date:  2015-06-05       Impact factor: 11.037

8.  Multiple myeloma-associated amyloidoma of the sacrum: case report and review of the literature.

Authors:  F M Klenke; C Wirtz; Y Banz; M J B Keel; N D Klass; U Novak; L M Benneker
Journal:  Global Spine J       Date:  2013-11-22

9.  Amyloid arthropathy associated with multiple myeloma: polyarthritis without synovial infiltration of CD20+ or CD38+ cells.

Authors:  Frank Pessler; Alexis R Ogdie; Christian T Mayer; Warren W Kretzschmar; Lie Dai; Ahmed M Elsaman; Eugene Einhorn; Veit Krenn; H Ralph Schumacher
Journal:  Amyloid       Date:  2013-11-28       Impact factor: 7.141

10.  Amyloidoma, an unusual cause of fracture.

Authors:  Frank Verhoeven; Clément Prati; Daniel Wendling
Journal:  Case Rep Rheumatol       Date:  2014-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.